Park Avenue Securities LLC Boosts Stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Park Avenue Securities LLC raised its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 64.8% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,368 shares of the biopharmaceutical company’s stock after purchasing an additional 538 shares during the quarter. Park Avenue Securities LLC’s holdings in Alnylam Pharmaceuticals were worth $322,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. Huntington National Bank raised its position in Alnylam Pharmaceuticals by 91.8% in the third quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 45 shares during the period. Hollencrest Capital Management purchased a new stake in shares of Alnylam Pharmaceuticals during the 3rd quarter valued at about $29,000. Washington Trust Advisors Inc. acquired a new position in Alnylam Pharmaceuticals during the 3rd quarter worth approximately $42,000. True Wealth Design LLC boosted its holdings in Alnylam Pharmaceuticals by 15,300.0% in the 3rd quarter. True Wealth Design LLC now owns 154 shares of the biopharmaceutical company’s stock worth $42,000 after acquiring an additional 153 shares during the period. Finally, Harvest Fund Management Co. Ltd acquired a new stake in Alnylam Pharmaceuticals in the third quarter valued at approximately $45,000. 92.97% of the stock is owned by institutional investors and hedge funds.

Alnylam Pharmaceuticals Price Performance

Shares of NASDAQ ALNY opened at $278.76 on Friday. The firm’s 50-day simple moving average is $247.13 and its 200 day simple moving average is $260.30. The company has a quick ratio of 2.69, a current ratio of 2.75 and a debt-to-equity ratio of 31.64. The stock has a market cap of $35.95 billion, a P/E ratio of -106.40 and a beta of 0.34. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $141.98 and a fifty-two week high of $304.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported ($0.87) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.36). The firm had revenue of $500.90 million during the quarter, compared to the consensus estimate of $532.91 million. The business’s revenue was down 33.3% on a year-over-year basis. During the same period in the previous year, the business earned $1.15 EPS. Equities analysts expect that Alnylam Pharmaceuticals, Inc. will post -2.24 EPS for the current year.

Insider Activity

In related news, Director Phillip A. Sharp sold 11,250 shares of Alnylam Pharmaceuticals stock in a transaction dated Thursday, January 23rd. The stock was sold at an average price of $275.00, for a total value of $3,093,750.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Yvonne Greenstreet sold 5,219 shares of the company’s stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $250.98, for a total value of $1,309,864.62. Following the completion of the sale, the chief executive officer now owns 78,880 shares of the company’s stock, valued at $19,797,302.40. This represents a 6.21 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 21,372 shares of company stock valued at $5,634,205. Insiders own 1.50% of the company’s stock.

Analyst Ratings Changes

ALNY has been the topic of a number of recent research reports. Wolfe Research cut shares of Alnylam Pharmaceuticals from a “peer perform” rating to an “underperform” rating in a research report on Tuesday, November 12th. Scotiabank boosted their price objective on shares of Alnylam Pharmaceuticals from $305.00 to $310.00 and gave the stock a “sector outperform” rating in a report on Friday, November 1st. Barclays raised their target price on Alnylam Pharmaceuticals from $295.00 to $329.00 and gave the company an “overweight” rating in a research note on Friday, November 1st. Needham & Company LLC reissued a “buy” rating and issued a $320.00 price target on shares of Alnylam Pharmaceuticals in a report on Monday, January 13th. Finally, StockNews.com lowered Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, January 9th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and nineteen have given a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $298.61.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.